Brief: Pfizer’s TALZENNA Plus XTANDI FDA-Approved For Earlier-Stage Metastatic Prostate Cancer
26/10/2026 18:36
BRIEF-Pfizer’s TALZENNA Plus XTANDI FDA-Approved For Earlier-Stage Metastatic Prostate Cancer Oct 26 (Reuters) - Pfizer Inc. PFE.N:
PFIZER’S TALZENNA PLUS XTANDI FDA-APPROVED FOR AN EARLIER METASTATIC PROSTATE CANCER TREATMENT SETTING
PFIZER - PHASE 3 TALAPRO-3 DATA SHOWS 52% REDUCTION IN RISK OF PROGRESSION OR DEATH
Source text: ID:nBw192xjza
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsBrief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma